

Edgar Filing: BALCHEM CORP - Form 8-K

BALCHEM CORP
Form 8-K
June 20, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): June 15, 2016

Balchem Corporation
(Exact name of registrant as specified in its charter)

Maryland 1-13648 13-2578432
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

New Hampton, NY 10958
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (845) 326-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07. Submission of Matters to a Vote of Security Holders.

Balchem Corporation (the "Company") held its Annual Meeting of Stockholders on June 15, 2016 ("Annual Meeting"). Set forth below is information regarding the results of the matters voted on by stockholders at the Annual Meeting:

(i) Election of three Class 1 Directors to serve until the annual Company's meeting of stockholders in 2019 and until their respective successors are elected and qualified:

<u>Director Nominee</u>	<u>Votes For</u>	<u>Votes Withheld</u>
Theodore L. Harris	26,222,925	506,549
Dino A. Rossi	26,222,635	506,839
Matthew D. Wineinger	26,251,660	477,814

(ii) Ratification of the appointment of RSM LLP as the Company's independent registered public accounting firm for the year ending December 31, 2016: 29,420,862 shares in favor, 234,102 shares against, 37,031 shares abstaining.

(iii) Advisory vote to approve the Company's executive compensation: 20,055,044 shares in favor, 6,609,781 shares against, 64,649 shares abstaining and 2,962,521 broker non-votes.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BALCHEM
CORPORATION

By: /s/ Matthew D. Houston
Matthew D. Houston
General Counsel and
Secretary

Dated: June 20, 2016
